HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellnx sued

This article was originally published in The Tan Sheet

Executive Summary

Multiple lawsuits consolidated in U.S. District Court in Boston claim the Canadian maker of Slimquick, NV and Liquid Hoodia dietary supplements made false weight-loss claims for the products and misrepresented the products' contents, the plaintiffs say Sept. 16. Wellnx's clients, now plaintiffs in the suit, were "cheated out of millions of dollars when Wellnx lied about what was in its products and what they would do to help them lose weight," says attorney David Barry of Boston-based Sugarman, Rogers, Barshak & Cohen. Independent lab testing found trace amounts or no weight-loss ingredients in Wellnx's products and clinical studies of green tea extract, the key ingredient in Slimquick and NV, show insignificant effects on weight loss, according to the lawyers' release. The National Advertising Division recommended Mississauga, Ontario-based Wellnx discontinue its claims for its Slimquick Extreme supplement due to lack of clinical data to support advertising claims (1"The Tan Sheet" July 21, 2008, p. 15)

You may also be interested in...



Slimquick Extreme Fails To Support “Clinically Proven” Claims – NAD

Clinical studies for Wellnx Life Sciences' weight-loss supplement Slimquick Extreme fail to meet standards necessary to support "clinically proven, strong, specific and quantified claims," the National Advertising Division says

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS136907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel